article thumbnail

When it comes to telehealth it’s not numbers

World of DTC Marketing

Still, they are more likely to continue use because of complex medical conditions or a nonclinical factor such as lack of transportation” OK, so where to start…First, let’s ask a fundamental question “why are people using telehealth? 83% believed the quality of the patient-physician communication was good.

Doctors 247
article thumbnail

Lexicon gets FDA approval for Inpefa to treat heart failure

Pharmaceutical Technology

Inpefa is a once-daily oral tablet indicated as an inhibitor of sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1). Lexicon Pharmaceuticals (Lexicon) has received approval from the US Food and Drug Administration (FDA) for its Inpefa drug to treat heart failure.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sourcing Insights from People Not Like Me

PM360

As the NIH states, sourcing feedback from just one demographic group can create a gap in fundamental understanding of diseases and responses to treatments, impacting clinical decisions, guidance that physicians offer to patients, and new treatment development. Ensure accessible locations, transportation, and time of day if in person.

article thumbnail

CMS Proposes New Services for Vulnerable Patients: Reimbursement for Community Health Integration, Social Determinants Risk Assessment, and Principal Illness Navigation

Nixon Gwilt Law

In the proposed 2024 Medicare Physician Fee Schedule (MPFS), the Centers for Medicare and Medicaid Services (CMS) proposes new CPT codes to facilitate reimbursement for healthcare providers who help patients overcome social and environmental health barriers. One of the greatest challenges facing the U.S. CMS defines SDOH as: “.including

article thumbnail

Delivery systems for biologics

European Pharmaceutical Review

A possible solution could be tailoring biologics delivery systems to facilitate in vivo transport for on-target delivery of the safeguarded payload. Notably, LNPs facilitate the transportation of large payloads, have limited immunogenicity, and allow for scalable manufacturing.

article thumbnail

FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS

Pharmaceutical Technology

Bylvay is a once-a-day, non-systemic ileal bile acid transport inhibitor (IBATi) that acts locally in the small intestine and has minimal systemic exposure.

article thumbnail

News release: Clarify Health unlocks greater clinical trial diversity with launch of Clarify Trials

Clarify Health

Clarify Trials’ analytics draws upon a dataset that includes patient-level SDoH data across an extensive set of factors, such as gender, race, ethnicity, income level, transportation access, housing stability, education level and health literacy.